Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Sandoz’ operation in Egypt has banded together with the Egyptian Cancer Society to introduce the firm’s biosimilar to Roche’s Rituxan/MabThera, three years after Hikma in-licensed a rituximab biosimilar from Celltrion.
Biogen’s biosimilar portfolio swung back to revenue growth in the third quarter of this year, as the US firm looks to diversify from anti-TNF products into ophthalmology and take operations global.
Biogen counted the cost of losing its monopoly on Tecfidera in the third quarter, with multiple generic entrants rushing in to the multi-billion-dollar opportunity.
Teva was accused by the US Department of Justice of violating anti-kickback law in donating money to charities that was later used to cover patient co-pays for Copaxone. In a rebuke aimed at having the suit dismissed, the Israeli manufacturer labelled the DoJ’s suit as “fatally flawed.”
Zydus Cadila has clocked up two tentative and four final abbreviated new drug application approvals in a short amount of time, including for Boehringer Ingelheim’s Jentadueto and the discontinued verapamil hydrochloride for injection.
H2 Pharma, which specializes in both generic and OTC liquid formulations, is looking to climb to the next level after receiving an equity investment from Ardian.